1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Sino Medical Sciences Technology Inc.

Sino Medical Sciences Technology Inc.

688108.SS
Sino Medical Sciences Technology Inc.CN flagShanghai Stock Exchange
18.36
CNY
-0.33
- -
7.67BMarket Cap
Sino Medical Sciences Technology Inc.
688108.SS
(Shanghai Stock Exchange)

Recent

price

18.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.3
1.41
1.07
1.16
0.73
0.48
0.48
0.87
1.23
1.22
1.08
Revenue per Share
0.14
0.29
0.25
0.24
0.05
-0.32
-0.4
-0.1
- -
0.11
0.15
Basic EPS, GAAP
-0.01
-0.03
- -
-0.11
-0.09
-0.53
-0.55
-0.03
0.16
0.27
-0.08
Free Cash Flow per Basic Share
0.08
0.04
- -
- -
0.09
- -
- -
0.01
0.01
0.01
0.01
Dividend per Share
0.72
1.17
1.11
1.4
1.11
0.9
0.53
0.44
0.48
0.52
0.61
Book Value per Share
0.62
2.16
1.49
2.22
1.7
1.53
1.31
1.2
0.72
0.76
1.07
Tangible Book Value per Share
205
228
357
375
450
409
406
396
374
430
408
Basic Weighted Avg Shares
266
322
380
436
327
194
193
343
459
525
441
Sales/Revenue/Turnover
15.04
25.36
26.94
23.61
4.17
-80.3
-103.71
-16.84
-1.57
14.31
20.96
Operating Margin (%)
16
18
21
28
38
65
63
63
78
75
- -
Depreciation Expense
29
66
89
90
22
-131
-162
-40
1
47
62
Net Income, GAAP
29.01
17.87
13.15
16.61
22.01
- -
- -
- -
- -
30.65
23.46
Effective Tax Rate (%)
10.79
20.54
23.45
20.65
6.87
-67.28
-84.2
-11.55
0.33
9
13.95
Profit Margin (%)
87
422
452
728
621
338
223
193
211
187
311
Working Capital
- -
- -
- -
- -
40
27
12
75
74
15
22
LT Debt
203
607
701
1,099
1,078
945
887
862
898
960
1,064
Total Equity
- -
16.19
13.43
9.47
0.95
- -
- -
- -
- -
4.68
6.18
Return on Invested Capital (%)
- -
31.6
26.39
18.69
3.35
- -
- -
- -
- -
12.33
14.46
Return on Capital (%)
- -
31.94
26.9
19.58
4.4
-30.19
-55.74
-20.31
0.84
23.48
28.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
197
118
LT Borrowings
- -
- -
9
LT Finance Leases
- -
15
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
416
418
Market Capitalization
8,406
5,713
8,293

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
520
514
Cash, Cash Equivalents & STI
- -
396
376
Accounts Receivable, Net
- -
25
28
Inventories
- -
89
93
Total Current Liabilities
- -
334
202
Payables & Accruals
- -
- -
- -
ST Debt
- -
197
118
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.04%
6.84%
Free Cash Flow
- -
-50.43%
89.59%
Net Income, GAAP
- -
444.1%
3,057.07%
Sales/Revenue/Turnover
- -
16.95%
14.53%
Total Cash Common Dividend
- -
642.61%
2.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
91
123
105
140
459
2025
101
140
- -
162
525
2026
140
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
0.01
- -
- -
- -
0.11
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Hylsamex S.A. de CV (HYLSAMXB.MX)
Vivos Therapeutics, Inc. (VVOS)
MEM Dental Technology Co., Ltd. (7555.TWO)
Opto Circuits (India) Ltd. (OPTOCIRCUI.NS)
LivaNova PLC (LIVN)
TELA Bio, Inc. (TELA)
Business
Sino Medical Sciences Technology Inc. (SINOMED) engages in the research, development, production and sales of high-end interventional medical devices for cardiovascular, cerebrovascular and structural heart diseases. The company offers a comprehensive portfolio of products across coronary intervention, neurointervention and structural heart disease segments; coronary intervention products include drug-eluting stents such as BuMA Supreme, HT Supreme healing-targeted drug coated stent system, BuMA biodegradable-drug-coating stent system and biodegradable magnesium drug-eluting stent system, coronary balloon catheters such as Tradent coronary scoring balloon catheter, SC Honkytonk PTCA balloon dilatation catheter, NC Rockstar non-compliant PTCA balloon dilatation catheter, Tytrak semi-compliant coronary balloon catheter and NC Thonic non-compliant coronary balloon catheter, and vascular access products such as Mariyana coronary guide extension catheter; neurointervention products encompass intracranial stenosis solutions like NOVA DES intracranial drug-eluting stent system, Neuro LPS intracranial balloon dilation catheter and COMETIU intracranial self-expanding drug stent system, ischemic stroke devices including COVESTAR balloon guide catheter, GHUNTER revascularization device, APACHI intracranial thrombosis aspiration catheter, TORR aspiration system and LEATUBE aspiration tubing, intracranial aneurysm treatments such as AUCURA coated flow diverter, and access delivery systems like OPTIMUS delivery catheter, APEX TRA radial access catheter system, Rayline micro catheter and NOVARAIL distal access catheter; structural heart disease offerings feature the AccuFit transapical mitral valve replacement (TMVR) system. Founded on September 21, 2007 and headquartered in Tianjin, China, SINOMED operates primarily in the domestic Chinese market with products used in over 2,000 hospitals and expanding global access through more than 200 patents in China, the United States and Europe. In a recent strategic move, the company agreed to acquire a 72.7% stake in eLum Technologies LLC from Decheng Capital to bolster its interventional device capabilities.